VX-222/TELAPREVIR IN COMBINATION WITH PEGINTERFERON-ALFA-2A AND RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE 1 HCV PATIENTS TREATED FOR 12 WEEKS: ZENITH STUDY, SVR12 INTERIM ANALYSIS

被引：0
|
作者：
Nelson, David R. [1 ]
Gane, Edward J. [2 ]
Jacobson, Ira M. [3 ]
Di Bisceglie, Adrian M. [4 ]
Alves, Katia [5 ]
Koziel, Margaret J. [5 ]
De Souza, Cynthia [5 ]
Kieffer, Tara L. [5 ]
George, Shelley [5 ]
Rosario, Maria [5 ]
Kauffman, Robert S. [5 ]
Sulkowski, Mark S. [6 ]
机构：
[1] Univ Florida, Coll Med, Gainesville, FL USA
[2] Auckland City Hosp, Auckland, New Zealand
[3] Weill Cornell Med Coll, New York, NY USA
[4] St Louis Univ, Sch Med, St Louis, MO USA
[5] Vertex Pharmacuet Inc, Cambridge, MA USA
[6] Johns Hopkins Univ, Baltimore, MD USA
来源：
HEPATOLOGY | 2011年 / 54卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：1435A / 1435A
页数：1
相关论文
共 50 条
  • [21] A STUDY OF TELAPREVIR COMBINED WITH PEGINTERFERON-ALFA-2A AND RIBAVIRIN IN SUBJECTS WITH WELL-DOCUMENTED NON-RESPONSE OR RELAPSE AFTER PREVIOUS PEGINTERFERON-ALFA-2A AND RIBAVIRIN TREATMENT: INTERIM ANALYSIS
    Shiffman, Mitchell L.
    Berg, Thomas
    Poordad, F. Fred
    Bronowicki, Jean-Pierre
    Muir, Andrew J.
    Gordon, Stuart C.
    George, Shelley
    Adda, Nathalie
    McHutchison, John G.
    HEPATOLOGY, 2008, 48 (04) : 1135A - 1136A
  • [22] VIROLOGICAL ANALYSIS OF PATIENTS RECEIVING TELAPREVIR ADMINISTERED Q8H OR Q12H WITH PEGINTERFERON-ALFA-2A OR -ALFA-2B AND RIBAVIRIN IN TREATMENT-NAiVE PATIENTS WITH GENOTYPE 1 HEPATITIS C: STUDY C208
    Marcellin, Patrick
    Forns, Xavier
    Goeser, Tobias
    Ferenci, Peter
    Nevens, Frederik
    Carosi, Giampiero
    Drenth, Joost P.
    De Backer, Koen
    van Heeswijk, Rudolf
    Luo, Donghan
    Picchio, Gaston
    Beumont-Mauviel, Maria
    HEPATOLOGY, 2009, 50 (04) : 395A - 395A
  • [23] ONCE DAILY NARLAPREVIR (NVR; SCH 900518) AND RITONAVIR (RTV) IN COMBINATION WITH PEGINTERFERON ALFA-2B/RIBAVIRIN (PR) FOR 12 WEEKS PLUS 12 WEEKS PR IN TREATMENT-NAIVE PATIENTS WITH HCV GENOTYPE 1 (G1): SVR RESULTS FROM NEXT-1, A PHASE 2 STUDY
    Vierling, John M.
    Poordad, F. Fred
    Lawitz, Eric
    Ghalib, Reem H.
    Lee, William M.
    Ravendhran, Natarajan
    Galati, Joseph S.
    Bacon, Bruce R.
    Flamm, Steven L.
    Balart, Luis A.
    Freilich, Bradley
    Schiff, Eugene R.
    Jacobson, Ira M.
    Kwo, Paul Y.
    Gordon, Stuart C.
    Sulkowski, Mark S.
    Jiang, Ruiyun
    Boparai, Navdeep
    Chaudhri, Eirum I.
    Treitel, Michelle A.
    Hughes, Eric A.
    Brass, Clifford A.
    Albrecht, Janice K.
    HEPATOLOGY, 2011, 54 : 1437A - 1438A
  • [24] EFFICACY AND SAFETY OF WEIGHT-BASED REGIMENS OF TARIBAVIRIN OR RIBAVIRIN, GIVEN WITH PEGINTERFERON ALFA-2B, AT 12 WEEKS AFTER TREATMENT (SVR12) IN NAIVE PATIENTS WITH GENOTYPE 1 CHRONIC-HEPATITIS C
    Poordad, F.
    Lawitz, E.
    Pozza, R.
    Shiffman, M.
    Bacon, B.
    Godofsky, E.
    Halliman, D.
    Heise, J.
    Chun, E.
    Hammond, J.
    JOURNAL OF HEPATOLOGY, 2009, 50 : S8 - S8
  • [25] COST-EFFECTIVENESS OF TELAPREVIR WITH PEGINTERFERON AND RIBAVIRIN FOR TREATMENT-NAIVE PATIENTS CHRONICALLY INFECTED WITH HCV OF GENOTYPE 1 IN JAPAN
    Ishida, H.
    Terai, S.
    Sakaida, I
    Inoue, Y.
    VALUE IN HEALTH, 2012, 15 (07) : A328 - A328
  • [26] Interim analysis results from a phase 2 study of telaprevir with peginterferon alfa-2a and ribavirin in treatment-naive subjects with hepatitis C
    Jacobson, Ira M.
    Everson, Gregory T.
    Gordon, Stuart C.
    Kauffman, Robert
    McNair, Lindsay
    Muir, Andrew
    McHutchison, John G.
    HEPATOLOGY, 2007, 46 (04) : 315A - 316A
  • [27] ACTIVITY OF TELAPREVIR ALONE OR IN COMBINATION WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE 2 AND 3 HEPATITIS-C PATIENTS: INTERIM RESULTS OF STUDY C209
    Foster, G. R.
    Hezode, C.
    Bronowicki, J. -P.
    Carosi, G.
    Weiland, O.
    Verlinden, L.
    van Heeswijk, R.
    Vangeneugden, T.
    Picchio, G.
    Beumont-Mauviel, M.
    JOURNAL OF HEPATOLOGY, 2009, 50 : S22 - S22
  • [28] Telaprevir in Combination with Peginterferon Alfa-2a and Ribavirin Increased Sustained Virologic Response in Genotype 1 Chronic HCV and Allowed for Shorter Treatment Duration in Treatment-naive and Prior Relapser Patients
    Everson, Gregory
    Dusheiko, Geoffrey
    Pol, Stanislas
    Nelson, David
    Muir, Andrew
    Andreone, Pietro
    Kauffman, Robert
    Adda, Nathalie
    Wright, Christopher
    Bengtsson, Leif
    Martin, Marie
    Sankoh, Abdul
    George, Shelley
    Sherman, Kenneth
    Jacobson, Ira
    Zeuzem, Stefan
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2011, 106 : S113 - S114
  • [29] TELAPREVIR IN COMBINATION WITH PEGINTERFERON ALFA2A AND RIBAVIRIN FOR 24 OR 48 WEEKS IN TREATMENT-NAiVE GENOTYPE 1 HCV PATIENTS WHO ACHIEVED AN EXTENDED RAPID VIRAL RESPONSE: FINAL RESULTS OF PHASE 3 ILLUMINATE STUDY
    Sherman, Kenneth E.
    Flamm, Steven L.
    Afdhal, Nezam H.
    Nelson, David R.
    Sulkowski, Mark S.
    Everson, Gregory T.
    Fried, Michael W.
    Kleber, Kristin
    Martins, Marie
    Sankoh, Abdul J.
    Kauffman, Robert S.
    George, Shelley
    Wright, Christopher I.
    Poordad, Fred
    HEPATOLOGY, 2010, 52 (04) : 401A - 402A
  • [30] Prove2 study: Treatment of chronic hepatitis C with telaprevir (TVR)in combination with peginterferon-alfa-2a with or without ribavirin, interim analysis results
    Hezode, Christophe
    Ferenci, Peter
    Dusheiko, Geoffrey M.
    Tran, Albert
    Grange, Jean-Didier
    Mathurin, Philippe
    Schmidt, Wolfgang E.
    Diepolder, Helmut
    Marcellin, Patrick
    Wedemeyer, Heiner
    Forestier, Nicole
    Mangels, Wendy
    Gharakhanian, Shahin
    Kauffman, Robert S.
    Alam, John
    Pawlotsky, Jean-Michel
    Zeuzem, Stefan
    GASTROENTEROLOGY, 2008, 134 (04) : A755 - A755
12345